At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 80 enrolled
Drug / intervention
Stendra 200 mg +1 moredrug
Likely dose
Stendra 200 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Double-Blind, Randomized, Placebo-Controlled, Single-Dose, Parallel Study to Assess the Effects of Avanafil (STENDRA™) on Multiple Parameters of Vision, Including, But Not Limited to Visual Acuity, Intraocular Pressure, Pupillometry, and Color Vision Discrimination, in Healthy Male Subjects
In Brief
A Phase 4 clinical trial evaluating Stendra 200 mg and Placebo for Vision. Completed, enrolled 80 participants across 1 site.
Detailed Summary
The purpose of this study is to see if Stendra causes any changes in vision, eye pressure, pupil dilation, and color vision in healthy males.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsVision
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
2014201520162017201820192020202120222023202420252026
Enrollment StartJan 2014
Primary CompletionJan 2014
First PostedJan 2014
TodayJul 2026
First PostedJan 10, 2014
Enrollment StartJan 1, 2014
Primary CompletionJan 1, 2014
TodayJul 2, 2026
Enrollment to primary: 0 daysPosted 12.5 years ago
Interventions
Stendra 200 mgdrug
Placebodrug